Vogt-Koyanagi-Harada disease following ChAdOx1 nCoV-19 and mRNA-1273 vaccination

Rujkorakarn, P.; Patamatamkul, S.

doi:10.1016/j.jfo.2022.09.017

Cited by 5 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 reported that the mean time between vaccination and onset of ocular complications was 9.4 days (median, 7 days; range, 1–30 days). Rujkorakarn and Patamatamkul 7 reported the recurrence of VKH disease 1 week after the third dose of an mRNA-based vaccine (mRNA-1273; Moderna). Our patient developed blurred vision 2 months after the third dose of the Pfizer COVID-19 vaccination, whereas Yasaka et al.…”

Section: Discussionmentioning

confidence: 99%

“…Although VKH disease has a good prognosis with adequate treatment, autoimmune responses to melanocytes frequently play a role in its occurrence. 3 Several reports have described the recurrence of VKH disease after coronavirus disease 2019 (COVID-19) vaccination [4][5][6][7] ; therefore, this disease necessitates long-term monitoring. Additionally, several reports have stated that VKH disease recurrence and VKH disease itself may be correlated with COVID-19 vaccination.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Reactivation of previously controlled Vogt–Koyanagi–Harada disease more than 46 years following COVID-19 vaccination: a case study

Muto,

Sakamoto,

Imaizumi

et al. 2024

J Int Med Res

View full text Add to dashboard Cite

We report a case of Vogt–Koyanagi–Harada (VKH) disease that recurred 46 years after initial treatment. A 59-year-old woman presented with a 2-month history of bilateral vision blurring. She had received her third dose of coronavirus disease 2019 (COVID-19) vaccination 4 months before the onset of blurring. The best-corrected visual acuity (BCVA) was 1.0 in the right eye and 0.15 in the left eye at the initial visit. Iritis and synechia were observed between the lens and iris bilaterally. A sunset glow fundus was found in both eyes with no serous retinal detachments or disc hyperemia. The patient had a history of VKH disease and had been treated with whole-body corticosteroid administration at another hospital when she was 13 years old. The patient was diagnosed with VKH disease recurrence, and oral corticosteroid therapy and corticosteroid eyedrop treatment were initiated. The treatment response was good. At the time of this writing, recurrence had not been observed for 14 months, and the BCVA was 1.0 in both eyes. To our knowledge, this case represents the longest recorded interval of VKH disease recurrence in the literature to date. COVID-19 vaccination might be the cause of long-term well-controlled disease recurrence.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Reactivation of previously controlled Vogt–Koyanagi–Harada disease more than 46 years following COVID-19 vaccination: a case study

Muto,

Sakamoto,

Imaizumi

et al. 2024

J Int Med Res

View full text Add to dashboard Cite

show abstract

“…A case of VKH with exudative detachment has also been observed in a 59-year-old man after the application of the ChAdOx1 nCoV-19 vaccine. 19 The patient improved with corticosteroids (CS) but needed long-term immunosuppressive therapy with methotrexate.…”

Section: Rhegmatogenous Retinal Detachment After Covid-19 Vaccinationmentioning

confidence: 99%

Retinal Detachment Following Vaccination against COVID-19: A Narrative Literature Review

Markov¹,

Zdravkov²,

Oscar³

2023

sjo

View full text Add to dashboard Cite

Retinal detachment (RD) refers to the anatomical separation of the neurosensory retina from the Retinal pigment epithelium, which, if untreated, ultimately leads to a loss of visual function and blindness. Three main types are recognised based on the pathogenesis: rhegmatogenous, associated with retinal tears/holes; tractional, where there is pulling on the retina from preretinal and/or vitreal fibrotic changes; and exudative or serous, in which the subretinal fluid is due to transudation, exudation, or impaired outer blood-retina barrier. The infection with SARS-CoV-2 has not been directly associated with any type of RD, except in cases of secondary infections or autoimmune conditions. Serous retinal detachment has very rarely been observed following the application of various vaccines against COVID-19, but only in the setting of central serous chorioretinopathy and uveitis. The single case of purported rhegmatogenous detachment has a highly improbable connection with the vaccination. All in all, the described complications have been extremely uncommon, more frequently treatable or self-resolving, and should not discourage COVID-19 vaccination.

show abstract

“…Despite VKH disease having a good prognosis with adequate treatment and autoimmune responses to melanocytes frequently playing a role in its occurrence [3]. Several reports presented VKH disease recurrence after coronavirus disease 2019 (COVID-19) vaccination [4][5][6][7]; therefore, this disease necessitates long-term monitoring.…”

Section: Introductionmentioning

confidence: 99%

Long-term recurrence interval of Vogt–Koyanagi–Harada disease post-COVID-19 vaccination: A case study

Muto¹,

Sakamoto

Imaizumi³

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose This study aimed to report a case of Vogt–Koyanagi–Harada (VKH) disease that recurred 46 years after initial treatment; the recurrence occurred 2 months after the third dose of coronavirus disease 2019 vaccination.Case report: A 59-year-old female patient had bilateral blurring for 2 months; she received her third dose of coronavirus disease 2019 vaccine 4 months before the onset of blurring. The best-corrected visual acuity was 1.0 in the right eye and 0.15 he left eye at the initial visit. Iritis and synechia between lens and iris were observed bilaterally. Sunset glow fundus was found in both eyes with no serous retinal detachments or disk hyperemia. She had a history of VKH disease and was treated with whole-body corticosteroid administration at another hospital when she was 13 years old. She was diagnosed with VKH disease recurrence, and oral corticosteroid intake and corticosteroid eyedrop treatments were initiated. The treatment response was good, but left synechia remained between the lens and iris in the left eye. Recurrence was not observed for 10 months until this study, and her best-corrected visual acuity was 1.0 in both eyes.Conclusion To our knowledge, this case represents the longest recorded interval of VKH disease recurrence in the literature.

show abstract

Vogt-Koyanagi-Harada disease following ChAdOx1 nCoV-19 and mRNA-1273 vaccination

Cited by 5 publications

References 13 publications

Reactivation of previously controlled Vogt–Koyanagi–Harada disease more than 46 years following COVID-19 vaccination: a case study

Reactivation of previously controlled Vogt–Koyanagi–Harada disease more than 46 years following COVID-19 vaccination: a case study

Retinal Detachment Following Vaccination against COVID-19: A Narrative Literature Review

Long-term recurrence interval of Vogt–Koyanagi–Harada disease post-COVID-19 vaccination: A case study

Contact Info

Product

Resources

About